Page 18 - 2020_09-Haematologica-web

Editorials
identified in a large proportion of the tumors across the distinct COO subtypes (Figure 1). Applying the publicly available LymphGen algorithm on the GOYA dataset could help classify patients into well-defined molecularly and clinically distinct subgroups. These newly character- ized subsets can identify patients with an unfavorable prognosis and may guide the development of new preci- sion therapies for these aggressive lymphomas.
Funding
Funded by a grant from Lymph&Co.
References
1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511.
2. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
3. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109(10):3879-3884.
4. Rosenwald A, Wright G, Chan WC, et al. The use of molecular pro- filing to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947.
5. Bolen CR, Klanova M, Trneny M, et al. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell- of-origin: data from the phase III GOYA study. Haematologica. 2020;105(9):2298-2307.
6. Schuetz JM, Johnson NA, Morin RD, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia. 2012;26(6):1383-1390.
7. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018;378(12):1107-1120.
8. Morschhauser F, Feugier P, Flinn IW, et al. Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R- CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): first safety, efficacy and biomarker analyses from the phase II CAVALLI study. Blood. 2018;132 (Supplement 1):782.
9. Morschhauser F, Salles G, McKay P, et al. Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2017;17(Suppl 2):S380-381.
10. Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016;128(2):185-194.
11. Ying CY, Dominguez-Sola D, Fabi M, et al. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol. 2013;14(10):1084-1092.
12. SchmitzR,WrightGW,HuangDW,etal.GeneticsandPathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378 (15):1396-1407.
13. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of dif- fuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690.
14. Wright GW, Huang DW, Phelan JD, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37 (4):551-568.e14.
15. Vermaat JS, Somers SF, de Wreede LC, et al. MYD88 mutations iden- tify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica. 2020;105(2):424-434.
16. Kraan W, Horlings HM, van Keimpema M, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lym- phomas presenting at immune-privileged sites. Blood Cancer J. 2013;3(9):e139.
17. Yonese I, Takase H, Yoshimori M, et al. CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential. Eur J Haematol. 2019;102(2):191-196.
18. Schrader AMR, Jansen PM, Willemze R, et al. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lym- phoma. Blood. 2018;131(18):2086-2089.
19. Kraan W, van Keimpema M, Horlings HM, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular dif- fuse large B-cell lymphoma. Leukemia. 2014;28(3):719-720.
20. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-926.
21. Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell. 2017;31(6):833-843.e5.
22. Grommes C, Pastore A, Palaskas N, et al. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017;7(9):1018-1029.
2196
Thrombin generation: a global coagulation procedure to investigate hypo- and hyper-coagulability
Armando Tripodi
IRCCS Ca’ Granda Maggiore Hospital Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milano, Italy
E-mail: ARMANDO TRIPODI - armando.tripodi@unimi.it doi:10.3324/haematol.2020.253047
The article by van Paridon et al.1 published in this issue of Haematologica on results of thrombin gen- eration (TG) in cardiovascular disease and mortali- ty, stemming from the Gutenberg Health Study, provides an opportunity to comment on TG as a global laboratory procedure to investigate hypo- and hyper-coagulability.
TG as a laboratory test was developed in the early 1950s by McFarlane and Biggs2 and was based on the acti- vation of coagulation in whole blood or plasma by trig- gers such as tissue factor or cephaline and calcium chlo-
ride. The amount of thrombin generated over time was titrated by sampling the mixture at different time points into a fibrinogen solution and the resultant clotting times interpolated from a dose-response calibration curve to derive thrombin concentrations. Years later, Hemker et al. made substantial changes.3-5 The fibrinogen solution was replaced by a chromogenic substrate specific for throm- bin, test plasma was defibrinated prior to testing and computer software was developed to derive the parame- ters stemming from the TG curve. These changes made
haematologica | 2020; 105(9)